Keywords
Analysis workflow, Whole Genome Sequencing, Germline variants, Somatic variants, Cancer
Analysis workflow, Whole Genome Sequencing, Germline variants, Somatic variants, Cancer
Whole-genome sequencing (WGS) and whole-exome sequencing (WES) technologies opens up new avenues for research and for clinical applications, with many large initiatives launched worldwide. While much effort has been invested in novel sequencing analysis software, the importance of providing and maintaining workflows to combine software in an efficient and reproducible manner has been underestimated and too few resources are typically dedicated to address this issue. This is of particular importance for somatic variant analysis and especially for analysis of complex cancer genomes, where a combination of tools is still required for optimal sensitivity and specificity and to detect various types of gene mutations and other abnormalities (Alioto et al., 2015). Some encouraging solutions have been presented in recent years, including SeqMule (Guo et al., 2015), SpeedSeq (Chiang et al., 2015), Bcbio-nextgen, and DNAp (Causey et al., 2018). While all of the above represent commendable and important efforts, we have not found any workflow solution that in our opinion fulfils all of the following important user aspects: (i) easy installation, (ii) robust portability across different compute environments, (iii) comprehensive documentation, (iv) transparent and easy-to-read code, and (v) extensive quality metrics reporting. Here we present Sarek, an easy-to-install community-maintained workflow, offering a complete and scalable solution for germline and somatic variant detection, annotation and quality control. Sarek supports several reference genomes and can handle data from WGS, WES and gene panels, and is intended to be used both as a production workflow at core facilities and as a stand-alone tool for individual research groups. By using Docker or Singularity containers, Sarek installs easily on all POSIX compatible systems such as Linux and Mac OS X and is designed to work on compute environments dedicated to handle sensitive personal data without direct internet access—a situation expected to become increasingly common with growing data security awareness.
Sarek offers a portable workflow for germline and somatic variant detection, annotation and quality control based on WGS, WES or gene panel data, using a range of state-of-the-art software and data resources in the field (Table 1, Figure 1). In the pre-processing step, sequence reads are aligned to the reference genome with BWA-MEM (Li, 2013), followed by deduplication and recalibration with GATK (McKenna et al., 2010). For germline samples, single-nucleotide variants and small insertion/deletions are detected with HaplotypeCaller (McKenna et al., 2010) and Strelka2 (Kim et al., 2018), and structural variations are detected with Manta (Chen et al., 2016) and TIDDIT (Eisfeldt et al., 2017). For somatic samples, somatic single-base mutations (SSM) and small somatic insertion/deletion mutations (SIM) are detected by GATK4 Mutect2 (Cibulskis et al., 2013) and Strelka2 (Kim et al., 2018). Somatic structural variants (including copy-number variation), as well as ploidy and sample purity are detected by Manta (Chen et al., 2016), ASCAT (Van Loo et al., 2010), and Control-FREEC (Boeva et al., 2012). All variants are annotated for potential functional effects with snpEff (Cingolani et al., 2012) and VEP (McLaren et al., 2016). Importantly, Sarek also generates a wide range of quality control metrics using FastQC, QualiMap (Okonechnikov et al., 2016), BCFtools (Li, 2011), Samtools (Li et al., 2009), and VCFtools (Danecek et al., 2011), visualized as an aggregated quality control review across samples with MultiQC (Ewels et al., 2016).
Sarek is implemented in Nextflow (Di Tommaso et al. 2017), a workflow language designed specifically for bioinformatics applications. Nextflow has a transparent design, making the Sarek code easy to read, adjust and extend. Compared to the Bpipe workflow language (used in for example DNAp), Nextflow offers superior support for different execution environments, like Slurm, Sun Grid Engine, LSF and Kubernetes, and includes native support for cloud compute environments including Google Cloud and AWS. Support for AWS batch gives the possibility to easily distribute thousands of batch jobs on Amazon Web Services. Sarek is part of a rapidly growing community effort of well documented and community-tested Nextflow pipelines, and adheres to the nf-core portability and documentation guidelines (Ewels et al., 2019). To facilitate easy installation and to ensure reproducibility, all Sarek required tools are managed in Docker or Singularity (Kurtzer et al., 2017) containers, or a Conda environment. While Docker is a widely appreciated container solution, it is not always allowed at high-performance computing centers because of the involved security risks, making Singularity the preferred choice at these sites (Kurtzer et al., 2017). This is of particular importance for computer environments designed for handling sensitive personal data, where a high level of data security has to be maintained across multiple projects and users.
Sarek can be installed and executed on any POSIX-compatible computer system. To run a full WGS analysis, including both germline and somatic variants from a tumour/normal dataset with 90x/90x read coverage, we recommend a minimum of 16 cores on a node with 128 GB RAM, and at least 4 TB available free storage (in addition to the initial FASTQ files) in the input/output working directory. Of this, about 1.4 TB will be allocated for BAM files, annotated VCF files and CNV files, but excluding GVCF files (Table 2). At the end of the run, 2.3 TB temporary data can be removed, unless the user plans to perform re-runs from intermediate processing states. Many processes are distributed across cores by dividing the genome into smaller chunks, each being handled as a separate core job, with all the results being merged and sorted in a final step. Some of the used software are parallelized by design, while for others Sarek uses a scatter-gather approach to efficiently distribute the processing load across CPU cores and reduce the wall clock runtime.
Sarek is run from a computer system with a local installation of Nextflow and support for either Conda environments, Docker or Singularity containers. Nextflow can automatically fetch the Sarek source code from GitHub. All software dependencies are encapsulated in Docker or Singularity containers which are downloaded from Docker Hub, or built in a new Conda environment using Bioconda (Grüning et al., 2018). As such, cumbersome software installations by the user are completely avoided. Configuration files allow tailoring to specific user needs and incomplete runs are easily restarted from any stage in the workflow process. Sarek comes with a small test dataset and a suite of tests to verify the installation. This is also used for Continuous Integration testing with GitHub Actions.
To test performance in terms of resource usage and biological results, Sarek was run on a medulloblastoma WGS tumour/normal dataset from a sample with high tumour cell content (∼98%), and with a curated “Gold Set” of verified somatic mutations from a previous benchmark study (Alioto et al., 2015). In line with the above benchmark study, Sarek (version 2.5.2) was executed with WGS germline and somatic variant calling using a 90X/90X tumour/normal dataset (accession number EGAD00001001859, read sets EGAR00001387019-24 and EGAR00001387025-32). Runs were performed on a single 48-thread node with a local direct attached storage (DAS): A Dell PowerEdge R740 server, with two Intel Xeon Gold 6126 with a total of 24 cores (48 threads) CPUs, 756 GB memory, and 100 TB SCv3020 Compellent Storage. The complete Sarek run including preprocessing followed by both germline and somatic variant calling and annotation took 48 hours and 21 minutes, and required about three times more storage than the original input data (Table 2). Notably, the complete Sarek run was executed by a single command, with fully automated installation, execution, and efficient job distributions of the more than 15 different software tools to complete the analysis and provide quality control metrics, without any manual intervention needed during the two-day run. To ensure that the Sarek output was biologically sound, we calculated precision, recall and F1 statistics for the Sarek output based on the “Gold Set” of somatic single-base mutations (SSM) and somatic insertion/deletion mutations (SIM) as previously defined (Alioto et al., 2015). Using the intersection of the output from the two somatic variant callers (GATK4 Mutect2 and Strelka2), Sarek provided accuracy measures for SSMs (F1 score = 0.80) and SIMs (F1 score = 0.58) in the top range of the 18 somatic variant calling procedures included in the original benchmarking study on this data set (Table 3), indicating that the workflow operates as intended. The sample purity was estimated to be 100%, as compared to 98% previously reported for this sample. For somatic structural variants and ploidy, no relevant benchmark data was available, and therefore no quantitative assessment beyond previously published results for the implemented software could be performed, but the integrity of the runs were checked by comparing the results of Manta, ASCAT, and Control-FREEC run within Sarek and as stand-alone.
Somatic caller | Recall | Precision | F1-score |
---|---|---|---|
SSM (Gold Set: n=1263) | |||
GATK4 Mutect2 | 0.80 | 0.45 | 0.58 |
Strelka2 | 0.77 | 0.29 | 0.42 |
Union (GATK4 Mutect2, Strelka) | 0.82 | 0.23 | 0.36 |
Intersection (GATK4 Mutect2, Strelka2) | 0.74 | 0.88 | 0.80 |
Benchmark median* | 0.68 | 0.78 | 0.71 |
SIM (Gold Set: n=347) | |||
GATK4 Mutect2 | 0.48 | 0.38 | 0.42 |
Strelka2 | 0.74 | 0.31 | 0.44 |
Union (GATK4 Mutect2, Strelka2) | 0.77 | 0.25 | 0.38 |
Intersection (GATK4 Mutect2, Strelka2) | 0.46 | 0.77 | 0.58 |
Benchmark median* | 0.34 | 0.71 | 0.48 |
* The median accuracy measures across 18 somatic variant calling procedures as previously reported (Alioto et al., 2015)
Sarek has been extensively tested and applied on various WGS datasets, including thousands of samples for germline variant analyses, and hundreds of paired tumour/normal samples for somatic mutation analyses. In addition, Sarek has also been successfully tested on WES data and gene panels. Below we present a standard use case with a tumour/normal WGS dataset as input, running both germline and somatic variant analyses.
For a somatic variant analysis, the user should provide the sequencing FASTQ files from both tumour and normal control tissue from the same individual, described in a tab-delimited TSV file (here: samples.tsv). Each line of the TSV file contains information about a sequence data file, including: The identifier of the individual, the gender (XX or XY), the status of the sample (0 for Normal or 1 for Tumour), the identifier of the sample, the sequencing lane (if samples are multiplexed across multiple lanes), and the paths to the FASTQ file of the first and second read in the read-pair. Relapse samples from the same individual are also supported.
Running Sarek with Singularity container on a computer system supporting Java 8 requires only installation of Nextflow and Singularity. A full analysis run starting from FASTQ files including mapping, recalibration, variant calling and annotation, as well as generating a full QC report can be invoked by a single Nextflow command:
> nextflow run nf-core/sarek -r 2.5.2 -profile singularity --input samples.tsv --tools Mutect2,Strelka,Manta,TIDDIT,ASCAT,ControlFREEC,snpEff,VEP
Nextflow will recognize the workflow name and will download the specified version (2.5.2) of the pipeline from GitHub, including the corresponding container, as well as fetching the required reference files from AWS-iGenomes. The default reference genome is human GRCh38, but Sarek also supports GRCh37 and nearly 30 other genomes directly accessible from iGenomes. Alternatively, users can manually supply Sarek with other reference genomes. Non-default parameters and links to local reference files are handled in accordance with nf-core guidelines. User configuration profiles can be stored locally or centrally at https://github.com/nf-core/configs.
A full Sarek run will produce a large number of output files, but the main results consist of (i) a set of annotated variants in VCF files from the various included tools for both germline and somatic variants, (ii) tumour sample purity and ploidy results for somatic samples, and (iii) a broad set of QC metrics. A detailed description of all output files is given at the Sarek documentation pages.
Human WGS is transforming medical research, and provides a foundation to develop novel clinical applications and improve health care. An important aspect to harvesting the potential of WGS is however to empower the research community with adequate bioinformatics tools, and reproducible bioinformatics workflows are important drivers of scientific progress by making complex processing of large datasets feasible for a wide range of researchers. While we are highly appreciative of existing workflows for cancer and non-cancer variant detection, we argue that there is no one-size-fits-all solution and more initiatives are needed to serve the large and diverse research user community, especially for WGS data. Sarek builds on a philosophy of reasonably narrow, independent workflows, written in the domain-specific language Nextflow. In our experience, this is an effective strategy to simplify workflow maintenance at sequencing core facilities, and to allow easy deployment and modifications by individual research groups. Sarek efficiently utilizes cloud and high-performance compute clusters and installs easily across compute environments. Sarek provides annotated VCF files, CNV reports and quality metrics for germline and cancer samples from raw FASTQ sequencing data in about 48 hours for 90X/90X WGS data (as demonstrated here), in a few hours for WES data, and within minutes for gene panels (in-house data, not presented here). Ongoing efforts aim to develop add-on ranking and visualization modules and to efficiently extract clinically and biologically relevant findings, to help advance basic and translational research.
Sarek is a portable and reproducible workflow to detect germline and somatic variants from WGS, WES and gene panel data. It includes extensive analysis and quality control metrics, while still being limited to a relatively narrow scope to achieve optimal usability, functionality and transparency. Sarek is flexible with a low threshold for user modifications, and is thus well adapted to the current requirements in the research community. Thanks to its design, it installs easily and reproducibly on all POSIX compatible computer systems, including secure compute environments for sensitive personal data with indirect Internet access.
European Genome-phenome Archive: A comprehensive assessment of somatic mutation detection in cancer using whole genome sequencing. https://www.ebi.ac.uk/ega/datasets/EGAD00001001859. Read sets EGAR00001387019-24 and EGAR00001387025-32 were analysed.
These data are held under restricted access. Readers wishing to apply for access to the data must first apply through the ICGC Data Access Compliance Office (https://icgc.org/daco) and complete the data access form. Access will be granted to those whose projects conform to the goals and policies of ICGC. Help with completing the data access form is available at https://icgc.org/daco/help-guide-section.
The workflow itself comes with a prebuilt profile with a complete configuration for automated testing, including links to a small test dataset.
Sarek is available at: https://nf-co.re/sarek.
Source code available at: https://github.com/nf-core/sarek.
Archived source code at time of publication: https://doi.org/10.5281/zenodo.3579102 (Garcia et al., 2019).
License: MIT License.
MK, BN and MN conceived the idea for Sarek. MG and SJ led the project. MG, SJ, ML, PIO, MM, JE, and SDL designed and implemented the workflow. JS, TDS, VW, MN, BN, PE and MK performed testing and provided design feedback. MG, SJ and BN wrote the manuscript with the help from all authors.
We are grateful for the valuable input from the Oslo University Hospital bioinformatics core facility (Oslo University Hospital), the T Martinsson lab (Gothenburg University), the A–C Syvänen lab (Uppsala University), and Alex Peltzer (Quantitative Biology Center, University of Tübingen). The National Genomics Infrastructure (NGI) and Uppsala Multidisciplinary Centre for Advanced Computational Science (UPPMAX) provided computational resources. Help with graphical design was provided by Dr. Jonas Söderberg (Uppsala university).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central Data from PMC are received and updated monthly. | - | - |
Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Yes
Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?
Yes
Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?
Yes
References
1. Yakneen S, Waszak SM, PCAWG Technical Working Group, Gertz M, et al.: Butler enables rapid cloud-based analysis of thousands of human genomes.Nat Biotechnol. 2020; 38 (3): 288-292 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Bioinformatics, cancer genetics, machine learning
Is the rationale for developing the new software tool clearly explained?
Yes
Is the description of the software tool technically sound?
Yes
Are sufficient details of the code, methods and analysis (if applicable) provided to allow replication of the software development and its use by others?
Yes
Is sufficient information provided to allow interpretation of the expected output datasets and any results generated using the tool?
Yes
Are the conclusions about the tool and its performance adequately supported by the findings presented in the article?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Diagnostic bioinformatics (variant calling pipelines) and variant interpretation
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 2 (revision) 04 Sep 20 | ||
Version 1 29 Jan 20 | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)